119 related articles for article (PubMed ID: 10981248)
1. A hypertensive reaction induced by concurrent use of selegiline and dopamine.
Rose LM; Ohlinger MJ; Mauro VF
Ann Pharmacother; 2000 Sep; 34(9):1020-4. PubMed ID: 10981248
[TBL] [Abstract][Full Text] [Related]
2. Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.
Ito D; Amano T; Sato H; Fukuuchi Y
J Neurol; 2001 Jun; 248(6):533-4. PubMed ID: 11499649
[No Abstract] [Full Text] [Related]
3. MAO-B inhibitors in Parkinson's disease.
Olanow CW
Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
[No Abstract] [Full Text] [Related]
4. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition.
LeWitt PA
Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310
[No Abstract] [Full Text] [Related]
5. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
6. MAO-B inhibitors for the treatment of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
[No Abstract] [Full Text] [Related]
7. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
10. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease.
Youdim MB; Riederer PF
Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584
[No Abstract] [Full Text] [Related]
11. Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males.
Barrett JS; Hochadel TJ; Morales RJ; Rohatagi S; DeWitt KE; Watson SK; Darnow J; Azzaro AJ; DiSanto AR
J Clin Pharmacol; 1997 Mar; 37(3):238-47. PubMed ID: 9089426
[TBL] [Abstract][Full Text] [Related]
12. Transdermal selegiline (Emsam).
Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
[No Abstract] [Full Text] [Related]
13. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.
Clarke A; Johnson ES; Mallard N; Corn TH; Johnston A; Boyce M; Warrington S; MacMahon DG
J Neural Transm (Vienna); 2003 Nov; 110(11):1257-71. PubMed ID: 14628190
[TBL] [Abstract][Full Text] [Related]
14. Rasagiline as a therapy for Parkinson's disease (PD).
Hermanowicz N
Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
[No Abstract] [Full Text] [Related]
15. Hypoglycemia caused by selegiline, an antiparkinsonian drug: can such side effects be predicted?
Rowland MJ; Bransome ED; Hendry LB
J Clin Pharmacol; 1994 Jan; 34(1):80-5. PubMed ID: 8132855
[TBL] [Abstract][Full Text] [Related]
16. Selegiline HC1: Selective MAO-type B inhibitor.
Koller WC; Giron LT
Neurology; 1990 Oct; 40(10 Suppl 3):suppl 58-60. PubMed ID: 2120616
[No Abstract] [Full Text] [Related]
17. Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus.
Hamaue N; Minami M; Terado M; Hirafuji M; Endo T; Machida M; Hiroshige T; Ogata A; Tashiro K; Saito H; Parvez SH
Neurotoxicology; 2004 Jan; 25(1-2):205-13. PubMed ID: 14697895
[TBL] [Abstract][Full Text] [Related]
18. MAO inhibitors: risks, benefits, and lore.
Wimbiscus M; Kostenko O; Malone D
Cleve Clin J Med; 2010 Dec; 77(12):859-82. PubMed ID: 21147941
[TBL] [Abstract][Full Text] [Related]
19. MAO-B inhibitor know-how: back to the pharm.
Lewitt PA
Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
[No Abstract] [Full Text] [Related]
20. Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.
Churchyard A; Mathias CJ; Lees AJ
Mov Disord; 1999 Mar; 14(2):246-51. PubMed ID: 10091617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]